← ANALYST RATINGS · TIPRANKS
Johnson & Johnson (JNJ): analyst forecast and price target
Analyst consensus
Moderate Buy12 Buy5 Hold0 Sell
Ratings of 17 analysts in the last 3 months12-month forecast
Based on 17 price targets given in the last 3 months, the average target is $289, the highest $320, the lowest $260. The average is +13.0% from the last price of $256.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $305 | Buy | +19.3% | Reiterated | 14.10.26on TipRanks 07:50 | +3.2%next day −0.5% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $261 → $270+3.4% | Hold | +5.7% | Reiterated | 14.10.26on TipRanks 06:30 | +3.2%next day −0.5% | ↗ |
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $290 → $280−3.4% | Buy | +9.6% | Reiterated | 13.10.26on TipRanks Oct 14 06:50 | −5.7%next day +3.2% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $294 → $292−0.7% | Buy | +14.3% | Assigned | 13.10.26on TipRanks Oct 14 06:35 | −5.7%next day +3.2% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $275 → $287+4.4% | Buy | +12.3% | Assigned | 13.10.26on TipRanks Oct 14 05:50 | −5.7%next day +3.2% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $275 | Hold | +7.6% | Reiterated | 13.10.26on TipRanks Oct 14 05:26 | −5.7%next day +3.2% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $296 → $295−0.3% | Buy | +15.4% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $287 → $298+3.8% | Buy | +16.6% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $289 → $295+2.1% | Buy | +15.4% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $275 → $289+5.1% | Hold | +13.1% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $291 → $295+1.4% | Buy | +15.4% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $300 → $296−1.3% | Buy | +15.8% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $260 | Hold | +1.7% | Reiterated | 12.10.26on TipRanks 08:10 | +0.9%next day −5.7% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $276 → $272−1.4% | Buy | +6.4% | Assigned | 12.10.26on TipRanks 07:35 | +0.9%next day −5.7% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $320 | Buy | +25.2% | Reiterated | 09.10.26on TipRanks 09:15 | +1.3%next day +0.9% · 5 days −0.3% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $287 | Buy | +12.3% | Reiterated | 06.10.26on TipRanks Oct 7 07:11 | +0.2%next day +1.7% · 5 days −2.3% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $298 → $303+1.7% | Buy | +18.6% | Reiterated | 05.10.26on TipRanks 07:16 | −1.9%next day +0.2% · 5 days +3.8% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $270 → $285+5.6% | Hold | +11.5% | Reiterated | 29.09.26on TipRanks 07:09 | −1.4%next day −0.9% · 5 days −6.7% | ↗ |
| Michael Nedelcovych★★★★★★★★★★#9548 · hits 48% · avg −1.2% | TD Cowen | $300 | Buy | +17.4% | Reiterated | 14.09.26on TipRanks Sep 15 02:06 | +0.7%next day +0.8% · 5 days −0.7% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $270 | Hold | +5.7% | Reiterated | 11.09.26on TipRanks 12:55 | −1.1%next day +0.7% · 5 days +1.8% | ↗ |
| Morten Herholdt★★★★★★★★★★#4305 · hits 69% · avg +8.7% | HSBC | $290 → $320+10.3% | Buy | +25.2% | Reiterated | 10.09.26on TipRanks 06:30 | +0.3%next day −1.1% · 5 days +0.8% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $282 | Buy | +10.3% | Reiterated | 25.08.26on TipRanks Aug 26 04:55 | +0.2%next day −1.2% · 5 days −0.2% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $290 → $300+3.4% | Buy | +17.4% | Assigned | 28.07.26on TipRanks Jul 29 11:00 | +0.1%next day +1.1% · 5 days −8.5% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $280 | Buy | +9.6% | Upgrade | 16.07.26on TipRanks 13:30 | +1.7%next day +2.2% · 5 days +5.4% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $258 → $265+2.7% | Buy | +3.7% | Reiterated | 16.07.26on TipRanks 08:55 | +1.7%next day +2.2% · 5 days +5.4% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $255 | Hold | −0.2% | Reiterated | 13.05.26on TipRanks May 14 05:15 | +2.2%next day −0.6% · 5 days −0.3% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Buy | — | Reiterated | 05.05.26on TipRanks May 6 02:30 | −0.2%next day −1.8% · 5 days −2.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Johnson & Johnson
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $288 at a price of $265 (+8.9%); now: $289 at $256 (+13.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 27 | 26 | 37 | 41 | 44 | 31 |
| Hold | 12 | 9 | 8 | 7 | 10 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 26.01.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.92 (from $2.74 to $3.04). Last quarter: $2.59.
Sales
Next quarter’s sales estimate — $26.4B (from $26.2B to $26.7B). Last quarter: $25.4B.
Best top-analyst consensus in the sector · Healthcare
About Johnson & Johnson
- CEO: Joaquin Duato
- Employees: 141,700
- One Johnson & Johnson Plaza, New Brunswick, NJ, 08933, US
- www.jnj.com
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Data from the stock’s TipRanks forecast page, read 19 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗